Show simple item record

dc.contributor.authorHijab, A
dc.contributor.authorCurcean, S
dc.contributor.authorTunariu, N
dc.contributor.authorTovey, H
dc.contributor.authorAlonzi, R
dc.contributor.authorStaffurth, J
dc.contributor.authorBlackledge, M
dc.contributor.authorPadhani, A
dc.contributor.authorTree, A
dc.contributor.authorStidwill, H
dc.contributor.authorFinch, J
dc.contributor.authorChatfield, P
dc.contributor.authorPerry, S
dc.contributor.authorMu Koh, D
dc.contributor.authorHall, E
dc.contributor.authorParker, C
dc.date.accessioned2021-05-04T14:56:22Z
dc.date.available2021-05-04T14:56:22Z
dc.date.issued2021-10-01
dc.identifier.citationClinical Genitourinary Cancer, 2021
dc.identifier.issn1558-7673
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4537
dc.identifier.doi10.1016/j.clgc.2021.03.020
dc.description.abstractBACKGROUND: Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration-resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. PATIENTS AND METHODS: This was a prospective, multicenter phase II study of radium-223 in 36 men with mCRPC and a reference cohort (n = 36) matched for fracture risk and not treated with radium-223. Bone fractures were assessed using whole-body magnetic resonance imaging. The primary outcome was risk of new fractures. RESULTS: Thirty-six patients were treated with up to six 4-week cycles of radium-223. With a median follow-up of 16.3 months, 74 new fractures were identified in 20 patients. Freedom from fracture was 56% (95% confidence interval, 35.3-71.6) at 12 months. On multivariate analysis, prior corticosteroid use was associated with risk of fracture. In the reference cohort (n = 36), 16 new fractures were identified in 12 patients over a median follow-up of 24 months. Across both cohorts, 67% of all fractures occurred at uninvolved bone. CONCLUSIONS: Men with mCRPC, and particularly those treated with radium-223, are at risk of fracture. They should receive a bone health agent to reduce the risk of fragility fractures.
dc.languageeng
dc.language.isoeng
dc.publisherCIG MEDIA GROUP, LP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleFracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223.
dc.typeJournal Article
dcterms.dateAccepted2021-03-27
rioxxterms.versionAM
rioxxterms.versionofrecord10.1016/j.clgc.2021.03.020
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical Genitourinary Cancer
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamClinical Trials & Statistics Unit
dc.contributor.icrauthorTovey, Holly
dc.contributor.icrauthorBlackledge, Matthew
dc.contributor.icrauthorHall, Emma


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0